Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

OFIX vs NVCR vs ATEC vs SYK vs HOLX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OFIX
Orthofix Medical Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$488M
5Y Perf.-64.6%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
ATEC
Alphatec Holdings, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.17B
5Y Perf.+74.2%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$112.69B
5Y Perf.+50.3%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%

OFIX vs NVCR vs ATEC vs SYK vs HOLX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OFIX logoOFIX
NVCR logoNVCR
ATEC logoATEC
SYK logoSYK
HOLX logoHOLX
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - DevicesMedical - Instruments & Supplies
Market Cap$488M$1.92B$1.17B$112.69B$16.97B
Revenue (TTM)$825M$674M$595M$25.12B$4.13B
Net Income (TTM)$-60M$-173M$-125M$3.25B$544M
Gross Margin69.0%75.2%89.6%63.5%52.8%
Operating Margin-4.0%-27.2%-9.6%22.4%17.5%
Forward P/E27.1x19.6x17.2x
Total Debt$229M$290M$620M$14.86B$2.63B
Cash & Equiv.$82M$103M$161M$4.01B$1.96B

OFIX vs NVCR vs ATEC vs SYK vs HOLXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OFIX
NVCR
ATEC
SYK
HOLX
StockMay 20May 26Return
Orthofix Medical In… (OFIX)10035.4-64.6%
NovoCure Limited (NVCR)10025.0-75.0%
Alphatec Holdings, … (ATEC)100174.2+74.2%
Stryker Corporation (SYK)100150.3+50.3%
Hologic, Inc. (HOLX)100142.6+42.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: OFIX vs NVCR vs ATEC vs SYK vs HOLX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Stryker Corporation is the stronger pick specifically for dividend income and shareholder returns and operational efficiency and capital deployment. ATEC also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
OFIX
Orthofix Medical Inc.
The Healthcare Pick

OFIX lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ATEC
Alphatec Holdings, Inc.
The Growth Play

ATEC ranks third and is worth considering specifically for growth exposure.

  • Rev growth 25.0%, EPS growth 15.0%, 3Y rev CAGR 29.6%
  • 25.0% revenue growth vs HOLX's 1.7%
Best for: growth exposure
SYK
Stryker Corporation
The Long-Run Compounder

SYK is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 187.1% 10Y total return vs ATEC's 225.4%
  • 1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend
  • 6.9% ROA vs NVCR's -16.5%, ROIC 11.4% vs -16.4%
Best for: long-term compounding
HOLX
Hologic, Inc.
The Income Pick

HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.41
  • Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.41, current ratio 3.75x
  • Lower P/E (17.2x vs 19.6x)
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthATEC logoATEC25.0% revenue growth vs HOLX's 1.7%
ValueHOLX logoHOLXLower P/E (17.2x vs 19.6x)
Quality / MarginsHOLX logoHOLX13.2% margin vs NVCR's -25.7%
Stability / SafetyHOLX logoHOLXBeta 0.41 vs NVCR's 2.20, lower leverage
DividendsSYK logoSYK1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)HOLX logoHOLX+37.1% vs ATEC's -37.8%
Efficiency (ROA)SYK logoSYK6.9% ROA vs NVCR's -16.5%, ROIC 11.4% vs -16.4%

OFIX vs NVCR vs ATEC vs SYK vs HOLX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OFIXOrthofix Medical Inc.
FY 2025
Global Spine
100.0%$688M
NVCRNovoCure Limited

Segment breakdown not available.

ATECAlphatec Holdings, Inc.
FY 2025
Products And Services
100.0%$764M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B
HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M

OFIX vs NVCR vs ATEC vs SYK vs HOLX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHOLXLAGGINGATEC

Income & Cash Flow (Last 12 Months)

HOLX leads this category, winning 2 of 6 comparable metrics.

SYK is the larger business by revenue, generating $25.1B annually — 42.2x ATEC's $595M. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOFIX logoOFIXOrthofix Medical …NVCR logoNVCRNovoCure LimitedATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…HOLX logoHOLXHologic, Inc.
RevenueTrailing 12 months$825M$674M$595M$25.1B$4.1B
EBITDAEarnings before interest/tax$102M-$165M$4M$6.3B$974M
Net IncomeAfter-tax profit-$60M-$173M-$125M$3.2B$544M
Free Cash FlowCash after capex-$4M-$48M$7M$4.3B$1000M
Gross MarginGross profit ÷ Revenue+69.0%+75.2%+89.6%+63.5%+52.8%
Operating MarginEBIT ÷ Revenue-4.0%-27.2%-9.6%+22.4%+17.5%
Net MarginNet income ÷ Revenue-7.3%-25.7%-21.1%+12.9%+13.2%
FCF MarginFCF ÷ Revenue-0.4%-7.1%+1.2%+17.1%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year+1.6%+12.3%-100.0%+11.4%+2.5%
EPS Growth (YoY)Latest quarter vs prior year+61.5%-100.0%+37.1%+56.0%-9.2%
HOLX leads this category, winning 2 of 6 comparable metrics.

Valuation Metrics

HOLX leads this category, winning 3 of 6 comparable metrics.

At 30.5x trailing earnings, HOLX trades at a 13% valuation discount to SYK's 35.0x P/E. On an enterprise value basis, HOLX's 17.4x EV/EBITDA is more attractive than ATEC's 3752.1x.

MetricOFIX logoOFIXOrthofix Medical …NVCR logoNVCRNovoCure LimitedATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…HOLX logoHOLXHologic, Inc.
Market CapShares × price$488M$1.9B$1.2B$112.7B$17.0B
Enterprise ValueMkt cap + debt − cash$635M$2.1B$1.6B$123.5B$17.6B
Trailing P/EPrice ÷ TTM EPS-5.29x-13.80x-8.07x35.03x30.53x
Forward P/EPrice ÷ next-FY EPS est.27.09x19.62x17.21x
PEG RatioP/E ÷ EPS growth rate2.36x
EV / EBITDAEnterprise value multiple3752.09x20.31x17.39x
Price / SalesMarket cap ÷ Revenue0.59x2.92x1.54x4.49x4.14x
Price / BookPrice ÷ Book value/share1.07x5.51x32.28x5.02x3.43x
Price / FCFMarket cap ÷ FCF422.56x26.31x18.44x
HOLX leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

SYK leads this category, winning 4 of 9 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-4 for ATEC. OFIX carries lower financial leverage with a 0.51x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATEC's 17.21x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs OFIX's 4/9, reflecting strong financial health.

MetricOFIX logoOFIXOrthofix Medical …NVCR logoNVCRNovoCure LimitedATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…HOLX logoHOLXHologic, Inc.
ROE (TTM)Return on equity-13.4%-50.8%-4.4%+15.0%+11.0%
ROA (TTM)Return on assets-7.0%-16.5%-15.8%+6.9%+6.1%
ROICReturn on invested capital-8.6%-16.4%-12.6%+11.4%+9.4%
ROCEReturn on capital employed-9.7%-28.9%-13.7%+13.0%+8.8%
Piotroski ScoreFundamental quality 0–945667
Debt / EquityFinancial leverage0.51x0.85x17.21x0.66x0.52x
Net DebtTotal debt minus cash$147M$187M$459M$10.8B$667M
Cash & Equiv.Liquid assets$82M$103M$161M$4.0B$2.0B
Total DebtShort + long-term debt$229M$290M$620M$14.9B$2.6B
Interest CoverageEBIT ÷ Interest expense-4.97x-96.80x-3.29x6.72x8.00x
SYK leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

SYK leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs ATEC's -37.8%. The 3-year compound annual growth rate (CAGR) favors SYK at 1.8% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricOFIX logoOFIXOrthofix Medical …NVCR logoNVCRNovoCure LimitedATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…HOLX logoHOLXHologic, Inc.
YTD ReturnYear-to-date-18.7%+28.3%-62.7%-15.2%+1.9%
1-Year ReturnPast 12 months+0.4%+1.1%-37.8%-22.5%+37.1%
3-Year ReturnCumulative with dividends-35.1%-75.7%-47.8%+5.5%-8.5%
5-Year ReturnCumulative with dividends-72.7%-91.3%-48.7%+21.5%+15.8%
10-Year ReturnCumulative with dividends-72.0%+30.3%+225.4%+187.1%+124.3%
CAGR (3Y)Annualised 3-year return-13.4%-37.6%-19.5%+1.8%-2.9%
SYK leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ATEC's 33.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOFIX logoOFIXOrthofix Medical …NVCR logoNVCRNovoCure LimitedATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…HOLX logoHOLXHologic, Inc.
Beta (5Y)Sensitivity to S&P 5001.21x2.20x1.13x0.55x0.41x
52-Week HighHighest price in past year$16.99$20.06$23.29$404.87$76.04
52-Week LowLowest price in past year$10.24$9.82$6.85$289.91$52.81
% of 52W HighCurrent price vs 52-week peak+71.0%+83.9%+33.3%+72.7%+100.0%
RSI (14)Momentum oscillator 0–10050.469.826.824.369.1
Avg Volume (50D)Average daily shares traded274K1.5M3.0M2.1M10.0M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: OFIX as "Hold", NVCR as "Buy", ATEC as "Buy", SYK as "Buy", HOLX as "Hold". Consensus price targets imply 222.6% upside for ATEC (target: $25) vs 3.9% for HOLX (target: $79). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.

MetricOFIX logoOFIXOrthofix Medical …NVCR logoNVCRNovoCure LimitedATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…HOLX logoHOLXHologic, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuyHold
Price TargetConsensus 12-month target$18.00$33.50$25.00$403.69$79.00
# AnalystsCovering analysts1715165042
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises34
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+4.4%
Insufficient data to determine a leader in this category.
Key Takeaway

HOLX leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). SYK leads in 2 (Profitability & Efficiency, Total Returns).

Best OverallHologic, Inc. (HOLX)Leads 3 of 6 categories
Loading custom metrics...

OFIX vs NVCR vs ATEC vs SYK vs HOLX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OFIX or NVCR or ATEC or SYK or HOLX a better buy right now?

For growth investors, Alphatec Holdings, Inc.

(ATEC) is the stronger pick with 25. 0% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OFIX or NVCR or ATEC or SYK or HOLX?

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus Stryker Corporation at 35. 0x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x.

03

Which is the better long-term investment — OFIX or NVCR or ATEC or SYK or HOLX?

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ATEC returned +225. 4% versus OFIX's -72. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OFIX or NVCR or ATEC or SYK or HOLX?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Orthofix Medical Inc. (OFIX) carries a lower debt/equity ratio of 51% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — OFIX or NVCR or ATEC or SYK or HOLX?

By revenue growth (latest reported year), Alphatec Holdings, Inc.

(ATEC) is pulling ahead at 25. 0% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Orthofix Medical Inc. grew EPS 30. 9% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, ATEC leads at 29. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OFIX or NVCR or ATEC or SYK or HOLX?

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OFIX or NVCR or ATEC or SYK or HOLX more undervalued right now?

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 27. 1x for Alphatec Holdings, Inc. — 9. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 222. 6% to $25. 00.

08

Which pays a better dividend — OFIX or NVCR or ATEC or SYK or HOLX?

In this comparison, SYK (1.

1% yield) pays a dividend. OFIX, NVCR, ATEC, HOLX do not pay a meaningful dividend and should not be held primarily for income.

09

Is OFIX or NVCR or ATEC or SYK or HOLX better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OFIX and NVCR and ATEC and SYK and HOLX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OFIX is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATEC is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. SYK pays a dividend while OFIX, NVCR, ATEC, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OFIX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 41%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

ATEC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 53%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform OFIX and NVCR and ATEC and SYK and HOLX on the metrics below

Revenue Growth>
%
(OFIX: 1.6% · NVCR: 12.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.